U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C27H29N5O3
Molecular Weight 471.5519
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ZANUBRUTINIB

SMILES

C=CC(=O)N1CCC(CC1)[C@]2([H])CCNc3c(c(-c4ccc(cc4)Oc5ccccc5)nn23)C(=O)N

InChI

InChIKey=RNOAOAWBMHREKO-QFIPXVFZSA-N
InChI=1S/C27H29N5O3/c1-2-23(33)31-16-13-18(14-17-31)22-12-15-29-27-24(26(28)34)25(30-32(22)27)19-8-10-21(11-9-19)35-20-6-4-3-5-7-20/h2-11,18,22,29H,1,12-17H2,(H2,28,34)/t22-/m0/s1

HIDE SMILES / InChI

Molecular Formula C27H29N5O3
Molecular Weight 471.5519
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED

Approval Year

Substance Class Chemical
Created
by admin
on Sat Jun 26 03:59:40 UTC 2021
Edited
by admin
on Sat Jun 26 03:59:40 UTC 2021
Record UNII
AG9MHG098Z
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ZANUBRUTINIB
INN   USAN  
Official Name English
ZANUBRUTINIB [WHO-DD]
Common Name English
PYRAZOLO(1,5-A)PYRIMIDINE-3-CARBOXAMIDE, 4,5,6,7-TETRAHYDRO-7-(1-(1-OXO-2-PROPEN-1-YL)-4-PIPERIDINYL)-2-(4-PHENOXYPHENYL)-, (7S)-
Systematic Name English
ZANUBRUTINIB [USAN]
Common Name English
BRUKINSA
Brand Name English
BGB-3111
Code English
(7S)-2-(4-PHENOXYPHENYL)-7-(1-(PROP-2-ENOYL)PIPERIDIN-4-YL)-4,5,6,7-TETRAHYDROPYRAZOLO(1,5-A)PYRIMIDINE-3-CARBOXAMIDE
Systematic Name English
ZANUBRUTINIB [ORANGE BOOK]
Common Name English
ZANUBRUTINIB [INN]
Common Name English
Classification Tree Code System Code
FDA ORPHAN DRUG 756920
Created by admin on Sat Jun 26 03:59:40 UTC 2021 , Edited by admin on Sat Jun 26 03:59:40 UTC 2021
FDA ORPHAN DRUG 527616
Created by admin on Sat Jun 26 03:59:40 UTC 2021 , Edited by admin on Sat Jun 26 03:59:40 UTC 2021
FDA ORPHAN DRUG 757020
Created by admin on Sat Jun 26 03:59:40 UTC 2021 , Edited by admin on Sat Jun 26 03:59:40 UTC 2021
FDA ORPHAN DRUG 757120
Created by admin on Sat Jun 26 03:59:40 UTC 2021 , Edited by admin on Sat Jun 26 03:59:40 UTC 2021
EU-Orphan Drug EU/3/19/2167
Created by admin on Sat Jun 26 03:59:40 UTC 2021 , Edited by admin on Sat Jun 26 03:59:40 UTC 2021
FDA ORPHAN DRUG 527516
Created by admin on Sat Jun 26 03:59:40 UTC 2021 , Edited by admin on Sat Jun 26 03:59:40 UTC 2021
NCI_THESAURUS C124801
Created by admin on Sat Jun 26 03:59:40 UTC 2021 , Edited by admin on Sat Jun 26 03:59:40 UTC 2021
NCI_THESAURUS C129825
Created by admin on Sat Jun 26 03:59:40 UTC 2021 , Edited by admin on Sat Jun 26 03:59:40 UTC 2021
FDA ORPHAN DRUG 527416
Created by admin on Sat Jun 26 03:59:40 UTC 2021 , Edited by admin on Sat Jun 26 03:59:40 UTC 2021
Code System Code Type Description
CAS
1691249-45-2
Created by admin on Sat Jun 26 03:59:40 UTC 2021 , Edited by admin on Sat Jun 26 03:59:40 UTC 2021
PRIMARY
RXCUI
2262435
Created by admin on Sat Jun 26 03:59:40 UTC 2021 , Edited by admin on Sat Jun 26 03:59:40 UTC 2021
PRIMARY
NCI_THESAURUS
C141428
Created by admin on Sat Jun 26 03:59:40 UTC 2021 , Edited by admin on Sat Jun 26 03:59:40 UTC 2021
PRIMARY
DRUG BANK
DB15035
Created by admin on Sat Jun 26 03:59:40 UTC 2021 , Edited by admin on Sat Jun 26 03:59:40 UTC 2021
PRIMARY
DRUG CENTRAL
5353
Created by admin on Sat Jun 26 03:59:40 UTC 2021 , Edited by admin on Sat Jun 26 03:59:40 UTC 2021
PRIMARY
PUBCHEM
135565884
Created by admin on Sat Jun 26 03:59:40 UTC 2021 , Edited by admin on Sat Jun 26 03:59:40 UTC 2021
PRIMARY
CAS
1651179-04-2
Created by admin on Sat Jun 26 03:59:40 UTC 2021 , Edited by admin on Sat Jun 26 03:59:40 UTC 2021
NO STRUCTURE GIVEN
FDA UNII
AG9MHG098Z
Created by admin on Sat Jun 26 03:59:40 UTC 2021 , Edited by admin on Sat Jun 26 03:59:40 UTC 2021
PRIMARY
INN
10555
Created by admin on Sat Jun 26 03:59:40 UTC 2021 , Edited by admin on Sat Jun 26 03:59:40 UTC 2021
PRIMARY
EVMPD
SUB195236
Created by admin on Sat Jun 26 03:59:40 UTC 2021 , Edited by admin on Sat Jun 26 03:59:40 UTC 2021
PRIMARY
Related Record Type Details
METABOLIC ENZYME -> INDUCER
Zanubrutinib is a weak inducer of CYP3A4 and CYP2C19 in vivo.
WEAK
EXCRETED UNCHANGED
URINE
BINDER->LIGAND
Zanubrutinib is approximately 94.2% bound to human plasma proteins in vitro, independent of concentration.
BINDING
EXCRETED UNCHANGED
FECAL
METABOLIC ENZYME -> INDUCER
Zanubrutinib induces CYP2B6 in vitro.
TARGET -> INHIBITOR
IRREVERSIBLE INHIBITOR
TRANSPORTER -> SUBSTRATE
METABOLIC ENZYME -> SUBSTRATE
MAJOR
TRANSPORTER -> INHIBITOR
METABOLIC ENZYME -> INDUCER
Zanubrutinib is a weak inducer of CYP3A4 and CYP2C19 in vivo.
WEAK
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
blood-to-plasma ratio PHARMACOKINETIC
Biological Half-life PHARMACOKINETIC
Tmax PHARMACOKINETIC ORAL ADMINISTRATION

Volume of Distribution PHARMACOKINETIC